Molecular & Medical Genetics, School of Medicine
Knight Cancer Institute
Cancer Early Detection Advanced Research center
Knight Cardiovascular Institute
Dr. Adey started out in biotechnology development at the University of Texas where he researched alternative applications of microarrays in the lab of Andrew D. Ellington, Ph.D. He later served as interim director of the UT microarray core facility and then helped set up the UT genome sequencing and analysis facility in the early days of next generation sequencing. He then completed his doctoral studies in the Molecular and Cellular Biology Program at the University of Washington in the lab of Jay Shendure, M.D., Ph.D. in the Genome Sciences Department. During his graduate tenure he pioneered the use of a novel transposase-based method for rapid, low-input DNA sequencing library construction, which he then extended to the genome-wide analysis of DNA methylation. He also applied long-range sequencing methods to produce the first haplotype resolved genome and epigenome of an aneuploid cell line, HeLa, where he investigated the role of haplotype and copy number on the epigenetic and transcriptional landscape. After completing his graduate studies he started his own independent group in the Department of Molecular and Medical Genetics at the Oregon Health and Science University, where he is now an Associate Professor. He is also a member of the Knight Cancer Institute, the Cancer Early Detection Advanced Research center, and the Knight Cardiovascular group.
The Adey Lab is currently focused on the development and deployment of single-cell technologies to profile a variety of epigenetic properties with an emphasis on chromatin accessibility. The primary technique is a combinatorial indexing strategy in addition to other platforms to increase library quality, cell quantity, incorporate spatial information and to reduce costs associated with single-cell experiments. The Adey Lab is currently applying these tools to study neurodevelopment as well as cancer biology.